PMC46 A REVIEW OF THE EVOLUTION OF HEALTH ECONOMIC MODELS OF SMOKING CESSATION  by Fisher, MI et al.
A28 Abstracts
models with inverse probability weighted (IPW) estimation techniques to address those 
challenges in a single model. METHODS: Generalized random effect models were used 
with weights that are calculated as inverse of probability being uncensored. The Gauss-
ian family and log link function were chosen. We applied a test to see if possible censor-
ing bias exists. We also calculated the deviation from the consistent value if standard 
pooled ordinary least squares were used. RESULTS: A total of 4,824 observations were 
used in the analysis. We obtained Medicare claim ﬁ les for the two years following a 
lung-cancer diagnosis. Costs had high kurtosis and skewness. Moreover, 30% of the
cases were censored. Therefore, their annual costs were not observed. The total cost 
of all care is $60K for the two years following a lung-cancer diagnosis and $55K for
incomplete cases. Results signiﬁ cantly diverged from the standard regression model 
(p  0.000). CONCLUSIONS: This paper applies the inverse probability weighted 
estimation to an inception cohort of patients newly diagnosed with lung cancer. Our
ﬁ ndings suggest that the standard regression model yields an inconsistent estimator due
to censoring bias. IPW least square estimation method removes that bias.
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OBJECTIVES: To review how health economic models of the cost-effectiveness of 
smoking cessation interventions have evolved over the last ten years. METHODS: The 
Medline database was searched via PubMed using the keywords ‘cost-effectiveness
models smoking cessation’. Articles not available or dating before 1998 were excluded.
The abstracts from these results were examined, and relevant studies were selected for 
the review. A bibliographic search was implemented on the selected studies and addi-
tional relevant studies were included. An extraction grid was built to record key 
comparable attributes of each included model as reported. RESULTS: Thirteen studies 
were included and extracted, dating from 1999–2008. The most common model 
design was Markov model simulations of hypothetical patient cohorts given various
interventions (6 studies). Reported cost perspectives have widened over the period: 
since 2004, societal perspectives have been the most common (7/8 studies) whereas
previously direct perspectives were more common (4/5 studies). Prior to 2004, 
3/5 studies were of UK patients whereas since then 4 were for the US, 3 Scandinavia.
The interventions included in the models were initially Nicotine Replacement 
Therapy (NRT) and bupropion (Zyban), but this has widened recently to also include 
varenicline (Champix), which was approved by the FDA in May 2006. It was not
possible to draw clear conclusions as to the values of cost, health outcome and cost-
effectiveness made given the wide variety of study designs, perspectives and countries 
modelled and the small number of studies. CONCLUSIONS: There is wide variety in
the nature of published health economic models of smoking cessation in terms of 
perspective, country and model structure. Some trends have been observed. Markov
models were the most common model design to use for modelling smoking cessation 
cost-effectiveness in the articles we reviewed.
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OBJECTIVES: Inverse propensity scores have been used in observational studies to 
reduce selection bias. To obtain estimates of the main effects, a pseudo data set is
created with weights copies of observations for each subject and analyzed with con-
ventional regression models. Currently variance estimation requires speciﬁ c formulas 
depending on type of outcomes. Our goal is to demonstrate a statistical approach to 
directly obtain the correct estimates of variance of the main effects (usually group
difference in outcomes) in regression models. METHODS: We carried out theoretical 
and simulation studies to show that the variance of the main effects estimated directly 
from regressions is underestimated, and that the type I error rate is higher due to the
inﬂ ated sample size in the pseudo data. We propose to use the stabilized weights to 
directly estimate both the main effect and its variance from conventional regression 
models. RESULTS: We applied the approach to a study examining the effectiveness
of serum potassium monitoring in reducing hyperkalemia-associated adverse events
among 27,362 diabetic patients newly-prescribed a renin-angiotensin-aldosterone
system (RAAS) inhibitor from three HMO Research Network sites. The relative risk
(with monitoring versus without monitoring) and conﬁ dence intervals were 0.52 (0.39, 
0.70) using stabilized weights compared to 0.52 (0.43, 0.64) using typical inverse
propensity scores. The sample size in the pseudo data using the stabilized weights was 
27,312 compared to 54,632 using inverse propensity scores. The sample size in the
pseudo data using the stabilized weights is slightly smaller than the original 27,362
largely due to missing covariates in the propensity score model. CONCLUSIONS: Our 
theoretical, simulation results, and real data example demonstrate that the use of the
stabilized weights in the pseudo data preserves the sample size of original data, pro-
duces correct estimation of the variance of main effect, and maintains an appropriate
type I error rate.
PMC48
“UNNATURAL” HISTORY: MODELING DISEASE PROGRESSION USING
OBSERVATIONAL DATA
Noyes K1, Bajorska A1, Chappel AR2, Schwid S1, Mehta LR2, Holloway R1, Dick A3
1University of Rochester School of Medicine, Rochester, NY, USA, 2University of Rochester, 
Rochester, NY, USA, 3The RAND Corporation, Pittsburgh, PA, USA
OBJECTIVES: Cost-effectiveness analysis requires comparison of outcomes in treated 
and untreated populations. Data from randomized clinical trials (RCT) do not provide 
progression rates representative of the general population, while treatment effects in
observational data may be biased due to non-randomization. We developed a novel 
approach for estimating untreated progression rates (controls) by using data from a 
nationally representative patient cohort, as well as RCT estimates. METHODS: We 
used data from the 2000–2005 Sonya Slifka multiple sclerosis (MS) cohort. Disease 
progression was characterized by disability-based disease states and relapses. We 
modeled probabilities of disease state transitions using a ﬁ rst-order annual Markov
model that adjusted for age, gender, disease duration, recent relapse rates, prior states,
and the speciﬁ c disease-modifying therapy (DMT). We developed an iterative multi-
nomial logistic regression algorithm, constraining the effects of DMT to match those 
reported by RCTs. RESULTS: After correcting for the DMT treatment effects and 
other observable risk factors, the probability of disability progression was greater for 
estimates based on all MS patients compared to the estimates based on untreated
individuals only. The 95% conﬁ dence intervals using the entire cohort (including 
treated and untreated individuals) were narrower than the intervals based on the 
subsample of untreated patients. CONCLUSIONS: Our results indicate that 
the untreated patients in our study had lower estimates of disease progression than
the treated patients would have had if they remained untreated. This suggests that
patients who forgo treatment are likely to have milder, slower progressing forms of 
MS. Correcting for treatment effects in a more inclusive group of patients likely pro-
vides a more realistic estimate of disease progression than simply characterizing pro-
gression in an untreated cohort. The use of a broader cohort also improves the
precision of disease progression estimates.
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OBJECTIVES: Classical methods assume that any and all information exists only in 
the data; Empirical Bayes (EB) methods assume, under certain conditions, that an 
informative prior can be calculated from the data. We conducted a simulation to show
the gains achieved by EB over classical methods. METHODS: We assumed that 
exchangeable units of analysis are available from which to calculate prior information. 
A non-parametric prior was estimated as a mixture of normal distributions. The simu-
lation used a two-level, four factor design to generate one-hundred and sixty scenarios.
The factors varied were: (1) the number of units of analysis [25, 50], (2) the sample 
size within each unit of analysis [10 or 25], (3) the number of distributions within the
mixture [2 or 4] and (4) the average effect sizes between the distributions within the 
prior mixture [0.2 and 0.8 standard deviations]. A prior was estimated for each sce-
nario using the EM algorithm across all units of analysis. This prior was combined
with the individual data to estimate posterior means; bootstrap methods were used to
estimate Bayesian conﬁ dence intervals. The Bayesian and Classical results were com-
pared within scenarios on four measures of “goodness”: (1) Absolute difference 
between the “true” mean and the classical and EB estimates, (2) frequency of the EB
mean being closest to the “true” mean, (3) average widths of the EB and classical
intervals, and the actual probability coverage of the estimated intervals. RESULTS:
EB methods were consistently closer in absolute difference and were more frequently 
closer to the “true” mean. EB conﬁ dence intervals were consistently narrower giving 
less uncertainty about the location of the true mean while maintaining the expected
probability coverage. CONCLUSIONS: Using “prior” information based on certain 
assumptions, Empirical Bayes methods provide better estimates of means and conﬁ -
dence intervals compared to classical methods.
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OBJECTIVES: Unlike the literature on estimators for cost data, not much attention
has been paid to the appropriate use of regression estimators for the analysis of health
beneﬁ ts in economic evaluation, i.e. EQ5D and QALYs. We explored the use of Beta 
regression models to address characteristics – such as ceiling effect, truncated distribu-
tion, and heteroschedasticity – typical of any quality of life data. METHODS: We 
developed both a single equation and a two-part Beta regression models (Classical and 
Bayesian), deﬁ ned incremental and marginal effects of covariates on the mean EQ5D, 
and proposed relevant estimators. Using the UK multicentre EVALUATE trial as a
motivating example, we compared results from OLS regression to those obtained from
our Beta-based estimators in terms of estimated mean treatment effect after controlling 
for other covariates. We complemented the case study with a microsimulation exercise. 
RESULTS: The OLS regression ﬁ t the EVALUATE trial EQ5D data as well as any of 
the advanced estimators based on Beta distribution. The estimated treatment effects
were 0.0099 (SE  0.011; 90% CI: 0.022, 0.038) under standard OLS regression 
